Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
A recent Nature Review Drug Discovery article caught our attention, a review of TIGIT as an IO target and the failed Phase 3 study of tiragolumab which is the TIGIT inhibitor from Roche.[1] The science writer interviewed a group of insiders that had a lead role in the development of Continue reading The Tiragolumab Saga & Tifacogin Flash-Backs
There are studies that are bound to succeed, and those that are likely to fail. A failed trial is nothing to be proud of – and in this case, it was a gamble against overwhelming odds. We feel the Gilead marketing department was pushing their luck big time with this Continue reading Obeldesivir Fails in Yet Another Study
Since the beginning of this millennium we have seen antibiotic R&D dwindle year after year. There are many reasons for this; while economics are often cited for this decline, the FDA and the ‘Guideline Wars’, i.e., those never ending discussions about regulatory requirements, have contributed to this trend in a Continue reading Progress Report: New Antibacterials In the Fight against MDR Bacteria